DOCSLIB.ORG

September, 2006

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
September, 2006 NIDA - Director's Report - September 2005 NIDA Home > Publications > Director's Reports Director's Report to the National Advisory Council on Drug Abuse - September, 2006 Index Research Findings Basic Neurosciences Research Basic Behavioral Research Behavioral and Brain Development Research Clinical Neuroscience Research Epidemiology and Etiology Research Prevention Research Research on Behavioral and Combined Treatments for Drug Abuse Research on Pharmacotherapies for Drug Abuse Research on Medical Consequences of Drug Abuse Services Research Clinical Trials Network Research Intramural Research International Research Program Activities Extramural Policy and Review Activities Congressional Affairs International Activities Meetings and Conferences Media and Education Activities Planned Meetings Publications Staff Highlights Grantee Honors https://archives.drugabuse.gov/DirReports/DirRep906/Default.html[11/17/16, 10:51:39 PM] NIDA - Director's Report - September 2005 Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? _ See our Contact Information. https://archives.drugabuse.gov/DirReports/DirRep906/Default.html[11/17/16, 10:51:39 PM] NIDA - Director's Report - September, 2006 NIDA Home > Publications > Director's Reports > September, 2006 Index Director's Report to the National Advisory Council on Drug Abuse - September, 2006 Index Research Findings - Basic Neurosciences Research Research Findings Phosphorylation of WAVE1 Regulates Actin Polymerization and Basic Neurosciences Dendritic Spine Morphology Research Basic Behavioral Research The connectionist theory posits that behavioral changes such as those produced by learning and addiction occur by strengthening the connections Behavioral and Brain between neurons called synapses. A neuron sending a signal to a neighboring Development Research neuron releases a chemical neurotransmitter into the synapse, which then Clinical Neuroscience diffuses across the synapse and binds to receptors located on the adjacent Research neuron. The receptors in most cases are located on specialized processes or Epidemiology and Etiology protrusions called dendritic spines. Drugs of abuse such as cocaine, nicotine, Research and opiates produce long term changes in the length of dendrites, the number of spines, and the shape of spines. An important molecule implicated by the Prevention Research Greengard laboratory in regulating the morphology of dendritic spines is cdk5, Research on Behavioral and a kinase that phosphorylates proteins, i.e., adds a high energy phosphate to Combined Treatments for proteins. Nobel Laureate Paul Greengard and his colleagues show that WAVE1 Drug Abuse (the Wiskott-Aldrich syndrome protein (WASP)-family verprolin homologous Research on protein 1) forms a complex with cdk5 and is phosphorylated by cdk5. Pharmacotherapies for Drug Phosphorylation of WAVE1 or the loss of WAVE 1 prevents actin, a major Abuse cytoskeletal protein from polymerizing and leads to a loss of dendritic spines. Research on Medical Dopamine, a neurotransmitter implicated in reward, decreases WAVE1 Consequences of Drug phosphorylation by cdk5 through a cAMP dependent dephosphorylation. The Abuse decrease in WAVE1 phosphorylation leads an increase in actin polymerization resulting in an increase in the number of spines. Thus, phosphorylation and Services Research dephosphorylation of WAVE1 regulates actin polymerization and dendritic Clinical Trials Network spines. Future research will determine the mechanism by which WAVE1 is Research dephosphorylated by cAMP. Kim, Y., Sung, J.Y., Ceglia, I., Lee, K-W., Ahn, J- Intramural Research H., Halford, J.M., Kim, A.M., Kwak, S.P., Park, J.B., Ryu, S.H., Schenck, A., Bardoni, B., Scott, J.D., Nairn, A.C., and Greengard, P. Phosphorylation of International Research WAVE1 Regulates Actin Polymerization and Dendritic Spine Morphology. Program Activities Nature, 442, pp. 814-817, 2006. Extramural Policy and Synaptopodin Regulates Cytoskeleton Through RhoA Review Activities The initiation and regulation of protruding subcellular structures, such as Congressional Affairs lamellipodia, filopodia formed during cell migration, and dendritic spines formed during neuronal synaptic growth, involves Rho family of small GTPases, International Activities including RhoA, Rac1 and Cdc42. It is through reorganization of the cytoskeleton that cells can move and make connections with other neurons. Meetings and Conferences How these molecules each function differently in regulating cytoskeletons, which support the subcellular structures is not clear. Dr. Mundel and colleagues Media and Education report that RhoA functions in stress fiber formation by interacting with a novel Activities protein called synaptopodin. First, using wild type podocytes as a model system, they found that knock-down of synaptopodin suppresses RhoA initiated Planned Meetings https://archives.drugabuse.gov/DirReports/DirRep906/DirectorReport1.html[11/17/16, 10:51:43 PM] NIDA - Director's Report - September, 2006 stress fibers, and overexpression of RhoA increases stress fibers in these cells. However, when they looked at podocytes lacking synaptopodin, the mRNA for Publications RhoA does not change. Additional search enabled them to discover that synaptopodin does not affect RhoA transcription, but blocks the targeting of Staff Highlights RhoA for degradation by Smurf1, a molecule which mediates ubiquitin induced protein degradation. The researchers further noticed that simply Grantee Honors overexpressing RhoA in synaptopodin silenced podocytes does not initiate more stress fibers, since synaptopodin also plays roles in activating RhoA when stress fiber forms. Since RhoA is downstream of many G-protein coupled receptors in memory and reward pathways, this work provides important insights about how such pathways can be activated or manipulated during drug abuse. Asanuma, K., Yanagida-Asanuma, E., Faul, C., Tomino, Y.,Kim, K. and Mundel, P. Synaptopodin Orchestrates Actin Organization and Cell Motility Via Regulation of RhoA Signalling. Nature Cell Biology, 8(5) pp. 485-491, 2006. Distinct Modes of Regulated Receptor Insertion to the Somatodendritic Plasma Membrane One of the most critical factors in determining whether or not two molecules with the potential to interact in a biological system will in fact interact is whether or not they ever "see" each other. It is, of course, essential for interaction between two molecules that the molecules be present in the same place at the same time so they might have the opportunity to interact. Even such co-localization is no guarantee of interaction, but it is guaranteed that they will not interact if they never co-localize. A critical step in ensuring the potential for interaction with other biologically relevant components is delivery of proteins and other cellular component to their site of action. In this study, the researchers have observed just such a delivery. Using cutting edge technology that allowed them to monitor molecular movement at the cell surface using a microscope, they report the observation of a member of the G- protein coupled receptor family inserting into the cell membrane of a primary cultured neuron upon exposure to an agonist of the receptor. They see not only delivery or receptor to the cell membrane at the outer surface of the cell, but have also learned about lateral movement of the receptors once at the surface. One of the intriguing aspects of their observations is that there appear to be two types of insertion events for this receptor. They have named these two events "transient" and "persistent" insertion referring to the length of time a cluster of receptors will remain clustered at the surface once delivered there before spreading out throughout the cell membrane. While both transient and persistent insertion events are observed at the surface of a given cell, continued exposure of the cell to receptor agonist causes a decrease in the frequency of the transient events while causing an increase in persistent events when compared to agonist washout conditions. It is important to note that these studies are consistent with the recycling of already existing receptors to the cell surface rather than delivery of newly synthesized receptors to the cell surface. The opioid receptors are from the same receptor family as the receptor studied here and recycling events of those receptors are believed to be closely linked to drug tolerance. Future studies looking specifically looking at the opioid receptors using this system will be valuable in trying to develop strategies to manage drug tolerance. Yudowski, G.A., Puthenveedu, M.A., and von Zastrow, M. Distinct Modes of Regulated Receptor Insertion to the Somatodendritic Plasma Membrane. Nature Neuroscience, 9(5), pp. 622-627, 2006. Regulation of DeltaFosB Stability by Phosphorylation Addiction is a chronic relapsing disease characterized by drug seeking behavior even in the face of adverse consequences. One mechanism thought to mediate addiction is long term changes in gene expression in which genes that encode proteins, the major regulators of cell function, are turned on or off. Addictive drugs acting through receptors on the surface of neuronal cells send signals to https://archives.drugabuse.gov/DirReports/DirRep906/DirectorReport1.html[11/17/16, 10:51:43 PM] NIDA - Director's Report
Load more

Recommended publications
  • Inhibition of G Protein-Activated Inwardly Rectifying K Channels by Phencyclidine
    244 Current Neuropharmacology, 2011, 9, 244-246 Inhibition of G Protein-Activated Inwardly Rectifying K+ Channels by Phencyclidine Toru Kobayashi1,2,*, Daisuke Nishizawa1 and Kazutaka Ikeda1 1Division of Psychobiology, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156-8585, Japan; 2Department of Project Programs, Center for Bioresource-based Researches, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, Niigata, Niigata 951-8585, Japan Abstract: Addictive drugs, such as opioids, ethanol, cocaine, amphetamine, and phencyclidine (PCP), affect many functions of the nervous system and peripheral organs, resulting in severe health problems. G protein-activated inwardly rectifying K+ (GIRK, Kir3) channels play an important role in regulating neuronal excitability through activation of various Gi/o protein-coupled receptors including opioid and CB1 cannabinoid receptors. Furthermore, the channels are directly activated by ethanol and inhibited by cocaine at toxic levels, but not affected by methylphenidate, methampheta- mine, and 3,4-methylenedioxymethamphetamine (MDMA) at toxic levels. The primary pharmacological action of PCP is blockade of N-methyl-D-aspartate (NMDA) receptor channels that are associated with its psychotomimetic effects. PCP also interacts with several receptors and channels at relatively high concentrations. However, the molecular mechanisms underlying the various effects of PCP remain to be clarified. Here, we investigated the effects of PCP on GIRK channels using the Xenopus oocyte expression system. PCP weakly but significantly inhibited GIRK channels at micromolar concentrations, but not Kir1.1 and Kir2.1 channels. The PCP concentrations effective in inhibiting GIRK channels overlap clinically relevant brain concentrations in severe intoxication. The results suggest that partial inhibition of GIRK channels by PCP may contribute to some of the toxic effects after overdose.
    [Show full text]
  • 5994392 Tion of Application No. 67375.734 Eb3-1685, PEN. T
    USOO5994392A United States Patent (19) 11 Patent Number: 5,994,392 Shashoua (45) Date of Patent: Nov.30, 1999 54 ANTIPSYCHOTIC PRODRUGS COMPRISING 5,120,760 6/1992 Horrobin ................................. 514/458 AN ANTIPSYCHOTICAGENT COUPLED TO 5,141,958 8/1992 Crozier-Willi et al. ................ 514/558 AN UNSATURATED FATTY ACID 5,216,023 6/1993 Literati et al. .......................... 514/538 5,246,726 9/1993 Horrobin et al. ....................... 424/646 5,516,800 5/1996 Horrobin et al. ....................... 514/560 75 Inventor: Victor E. Shashoua, Brookline, Mass. 5,580,556 12/1996 Horrobin ................................ 424/85.4 73 Assignee: Neuromedica, Inc., Conshohocken, Pa. FOREIGN PATENT DOCUMENTS 30009 6/1981 European Pat. Off.. 21 Appl. No.: 08/462,820 009 1694 10/1983 European Pat. Off.. 22 Filed: Jun. 5, 1995 09 1694 10/1983 European Pat. Off.. 91694 10/1983 European Pat. Off.. Related U.S. Application Data 59-025327 2/1984 Japan. 1153629 6/1989 Japan. 63 Continuation of application No. 08/080,675, Jun. 21, 1993, 1203331 8/1989 Japan. abandoned, which is a continuation of application No. 07/952,191, Sep. 28, 1992, abandoned, which is a continu- (List continued on next page.) ation of application No. 07/577,329, Sep. 4, 1990, aban doned, which is a continuation-in-part of application No. OTHER PUBLICATIONS 07/535,812,tion of application Jun. 11, No. 1990, 67,375.734 abandoned, Eb3-1685, which is a continu-PEN. T. Higuchi et al. 66 Prodrugs as Noye Drug Delivery Sys 4,933,324, which is a continuation-in-part of application No.
    [Show full text]
  • New Mesh Headings for 2019 Listed in Alphabetical Order with Heading, Scope Note, Annotation (AN), Previous Indexing (PI), and Tree Locations
    New MeSH Headings for 2019 Listed in alphabetical order with Heading, Scope Note, Annotation (AN), Previous Indexing (PI), and Tree Locations 17 alpha-Hydroxyprogesterone Caproate Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS. Tree locations: 17-alpha-Hydroxyprogesterone D04.210.500.745.745.654.829.395.400.500 D06.472.334.851.687.750.478.400.250 2-Methoxyestradiol A metabolite of estradiol that lacks estrogenic activity and inhibits TUBULIN polymerization. It has antineoplastic properties, including inhibition of angiogenesis and induction of APOPTOSIS. Tree locations: Estradiol D04.210.500.365.415.248.830 D06.472.334.851.437.500.750 5-Methoxypsoralen A linear furanocoumarin that has phototoxic and anti-inflammatory properties, with effects similar to METHOXSALEN. It is used in PUVA THERAPY for the treatment of PSORIASIS. Tree locations: Furocoumarins D03.383.663.283.446.794.688 D03.633.100.150.446.794.688 D03.633.300.770.688 Abciximab A Fab fragment of the chimeric monoclonal antibody 7E3 that binds to the glycoprotein IIb-IIIa receptor of human platelets, and blocks PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX, potently inhibiting PLATELET AGGREGATION. It is used in treatment of refractory unstable angina, and for prevention of ischemic complications in patients undergoing percutaneous coronary procedures such as ANGIOPLASTY; ATHERECTOMY; or stenting. Tree locations: Antibodies, Monoclonal, Humanized D12.776.124.486.485.114.224.060.125 D12.776.124.790.651.114.224.060.125 D12.776.377.715.548.114.224.200.125 Immunoglobulin Fab Fragments D12.644.541.500.650.125 D12.776.124.486.485.680.650.125 D12.776.124.790.651.680.650.125 D12.776.377.715.548.680.650.125 Acamprosate Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.
    [Show full text]
  • Novel Benzazepine Derivatives
    (19) & (11) EP 2 133 340 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.12.2009 Bulletin 2009/51 C07D 223/16 (2006.01) A61K 31/55 (2006.01) A61P 25/00 (2006.01) (21) Application number: 09168438.1 (22) Date of filing: 18.12.2003 (84) Designated Contracting States: • Witherington, Jason AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Stevenage, Hertfordshire SG1 2NY (GB) HU IE IT LI LU MC NL PT RO SE SI SK TR • Bamford, Mark James Stevenage, Hertfordshire SG1 2NY (GB) (30) Priority: 20.12.2002 GB 0229820 • Dean, David Kenneth 02.06.2003 GB 0312607 Harlow, Essex CM19 5AW (GB) (62) Document number(s) of the earlier application(s) in (74) Representative: Breen, Anthony Paul et al accordance with Art. 76 EPC: GlaxoSmithKline 03785885.9 / 1 572 215 Corporate Intellectual Property (CN9.25.1) 980 Great West Road (71) Applicant: Glaxo Group Limited Brentford, Middlesex TW8 9GS (GB) Greenford, Middlesex UB6 0NN (GB) Remarks: (72) Inventors: This application was filed on 21-08-2009 as a • Sehmi, Sanjeet Singh divisional application to the application mentioned Harlow, Essex CM19 5AW (GB) under INID code 62. • Wilson, David Matthew Stevenage, Hertfordshire SG1 2NY (GB) (54) Novel benzazepine derivatives (57) The present invention relates to novel ben- zazepine derivatives having pharmacological activity, processes for their preparation, to compositions contain- ing them and to their use in the treatment of neurological and psychiatric disorders. More specifically, the invention relates to a com- pound of formula (I) or a pharmaceutically acceptable salt thereof: wherein formula (I) is as defined herein.
    [Show full text]
  • Behavioral Pharmacology of Dopamine D2 and D3 Receptor Agonists and Antagonists in Rats
    Behavioral Pharmacology of Dopamine D2 and D3 Receptor Agonists and Antagonists in Rats. by Gregory T. Collins A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmacology) in The University of Michigan 2008 Doctoral Committee: Professor James H. Woods, Chair Professor Margaret E. Gnegy Professor Shaomeng Wang Assistant Professor Roger K. Sunahara © Gregory T. Collins 2008 DEDICATION This thesis is dedicated to my parents, Thomas and Shirley Collins, without whom none of this would have been possible. Your continual support and encouragement throughout all of my endeavors has meant more than you will ever know. Thank you. ii ACKNOWLEDGMENTS First and foremost, I would like to thank my mentor, James Woods. You have been an exceptional mentor to me; I have learned more than I could have ever hoped. It has been a pleasure to work with someone who is so passionate and knowledgable, someone who has not only continued to challenge me, but has also provided an outstanding environment in which to study behavioral pharmacolgy. I truly feel lucky to have been able to learn from you. Of course, I also have to thank Gail Winger who has been a second mentor to me throughout the years. The support, encouragement, guidance, and patience that the two of you have provided has made for an exceptional experience. Thank you. I would also like to thank my committee, James Woods, Roger Sunahara, Peggy Gnegy and Shaomeng Wang. I am grateful to have been able to work with and learn from all of you over the years.
    [Show full text]
  • Problems of Drug Dependence 1998: Proceedings of the 60Th Annual Scientific Meeting the College on Problems of Drug Dependence, Inc
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc. U.S. Department of Health and Human Services1 • National79 Institutes of Health Problems of Drug Dependence, 1998: Proceedings of the 66th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. Virginia Commonwealth University NIDA Research Monograph 179 1998 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse 6001 Executive Boulevard Bethesda, MD 20892 ACKNOWLEDGEMENT The College on Problems of Drug Dependence, Inc., an independent, non-profit organization conducts drug testing and evaluations for academic institutions, government, and industry. This monograph is based on papers or presentations from the 60th Annual Scientific Meeting of the CPDD, held in Scottsdale, Arizona, June 12-17, 1998. In the interest of rapid dissemination, it is published by the National Institute on Drug Abuse in its Research Monograph series as reviewed and submitted by the CPDD. Dr. Louis S. Harris, Department of Pharmacology and Toxicology, Virginia Commonwealth University was the editor of this monograph. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published materials as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • United States Patent Office Patiented Mar
    3,126,373 United States Patent Office Patiented Mar. 24, 1964 2 invention, and 5-(3'-dimethylaminopropyl)-5H-dibenz 3,126,373 (b,fl-azepine (SK & F #5355) are given in Table 1. 5-MONOALKYAMNOPROPYL-5H The effective dose value for 50% of the test animals DBENZ-b,f-AZEPINES (ED50) is determined by subcutaneous (s.c.) administra Paul N. Craig, Roslyn, Pa., assignor to Smith Kline & 5 tion of the test compound at graduated doses to groups French Laboratories, Philadelphia, Pa., a corporation of 15 rats per dose. of Pennsylvania TABLE 1. No Drawing. Filled Feb. 2, 1962, Ser. No. 170,806 1 Claim. (C. 260-239) Calmative Activity Anti-Furmethide Protective Effect Activity This invention relates to 5-monoalkylaminopropyl-5H 10 Against Stress (Isolated Rabbit dibenz-b,f-azepines which have useful therapeutic activ Induced Ulcers Jejunum) ity, specifically as general central nervous system depres Structure and No. Mini sants and particularly as antiemetics, tranquilizers, calma ED50 Relative mum Relative mg/kg. Potency Dose, Potency tives, anti-histaminics, spasmolytics, antishock agents and S.C. mg.150 potentiators of analgetics or anesthetics. 15 CC. The novel 5-monoalkylaminopropyl-5H-dibenz-Ib,f- azepines of this invention are represented by the general SK & F #5355 formula: FORMUL.A. i 20 9 0 CEs-CE. 2.0 1. 0.01 1. 8 2 N CHs f b / 8-R, (CH2)3N NS H 25 CI 6 4. / CH2CH2CH-N SK & F #13943 R when: R1 and Ra represent hydrogen or chlorine; and 30 0.13 15.4 0.04 .25 R represents lower alkyl of from 1 to 4 carbon atoms, YN/A preferably methyl.
    [Show full text]
  • List Item Minutes of the CHMP Meeting 28-31 May 2018 (PDF/1.03
    30 July 2018 EMA/CHMP/442216/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Committee for medicinal products for human use (CHMP) Minutes of the meeting on 28-31 May 2018 Chair: Tomas Salmonson – Vice-Chair: Harald Enzmann Disclaimers Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, the minutes are a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0069221A1 Kosoglou Et Al
    US 2003OO69221A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0069221A1 KOSOglou et al. (43) Pub. Date: Apr. 10, 2003 (54) COMBINATIONS OF STEROL ABSORPTION Related U.S. Application Data INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF (60) Provisional application No. 60/323,842, filed on Sep. WASCULAR CONDITIONS 21, 2001. Provisional application No. 60/264,396, filed on Jan. 26, 2001. Provisional application No. (75) Inventors: Teddy Kosoglou, Jamison, PA (US); 60/264,600, filed on Jan. 26, 2001. Provisional appli Rudyard J. Ress, Flemington, NJ (US); cation No. 60/264,275, filed on Jan. 26, 2001. John T. Strony, Lebanon, NJ (US); Enrico P. Veltri, Princeton, NJ (US); Publication Classification William Hauer, Warren, NJ (US) (51) Int. Cl. ................................................ A61K 31/397 Correspondence Address: (52) U.S. Cl. ........................................................ 514/210.02 SCHERING-PLOUGH CORPORATION PATENT DEPARTMENT (K-6-1, 1990) (57) ABSTRACT 2000 GALLOPING HILL ROAD KENILWORTH, NJ 07033-0530 (US) The present invention provides compositions, therapeutic (73) Assignee: Schering Corporation combinations and methods including: (a) at least one Sterol absorption inhibitor and (b) at least one cardiovascular agent (21) Appl. No.: 10/057,339 different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and (22) Filed: Jan. 25, 2002 lowering plasma levels of Sterols. US 2003/0069221A1 Apr. 10, 2003 COMBINATIONS OF STEROL ABSORPTION ever means, less cholesterol is delivered to the liver. The INHIBITOR(S) WITH CARDIOVASCULAR consequence of this action is decreased hepatic lipoprotein AGENT(S) FOR THE TREATMENT OF WASCULAR (VLDL) production and an increase in the hepatic clearance CONDITIONS of plasma cholesterol, mostly as LDL.
    [Show full text]
  • Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders
    Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology Volume 2012, Article ID 259349, 14 pages doi:10.1155/2012/259349 Review Article Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders Lie-Hang Shen, Mei-Hsiu Liao, and Yu-Chin Tseng Institute of Nuclear Energy Research, Jiaan Village, Lungtan Township, Taoyuan 32546, Taiwan Correspondence should be addressed to Yu-Chin Tseng, [email protected] Received 15 December 2011; Accepted 27 January 2012 Academic Editor: David J. Yang Copyright © 2012 Lie-Hang Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Dopamine is the most intensely studied monoaminergic neurotransmitter. Dopaminergic neurotransmission plays an important role in regulating several aspects of basic brain function, including motor, behavior, motivation, and working memory. To date, there are numerous positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiotracers available for targeting different steps in the process of dopaminergic neurotransmission, which permits us to quantify dopaminergic activity in the living human brain. Degeneration of the nigrostriatal dopamine system causes Parkinson’s disease (PD) and related Parkinsonism. Dopamine is the neurotransmitter that has been classically associated with the reinforcing effects of drug abuse. Abnormalities
    [Show full text]
  • 20 October 2011 (20.10.2011) V I A
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date r /1 1 20 October 2011 (20.10.2011) V I A (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/10 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/DK20 11/00003 1 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 16 April 201 1 (16.04.201 1) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/325,1 60 16 April 2010 (16.04.2010) US (84) Designated States (unless otherwise indicated, for every PA 2010 70149 16 April 2010 (16.04.2010) DK kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, NUEVOLUTION A S [DK/DK]; R0nnegade 8, 5, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, DK-2100 Copenhagen (DK).
    [Show full text]
  • (CHMP) Draft Agenda for the Meeting on 28-31 May 2018
    28 May 2018 EMA/CHMP/352527/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Committee for medicinal products for human use (CHMP) Draft agenda for the meeting on 28-31 May 2018 Chair: Tomas Salmonson – Vice-Chair: Harald Enzmann 28 May 2018, 13:00 – 19:30, room 2A 29 May 2018, 08:30 – 19:30, room 2A 30 May 2018, 08:30 – 19:30, room 2A 31 May 2018, 08:30 – 15:00, room 2A Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted.
    [Show full text]